Léčba erlotinibem nemocných s nemalobuněčným karcinomem plic - efekt snížené dávky při závažných nežádoucích účincích.

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Title in English	Erlotinib treatment in patient with non-small cell lung cancer (NSCLC): The Effect of lowered dose in serious adverse events
Authors	PEŠEK M. KREJČÍ J. SKŘIČKOVÁ Jana
Year of publication	2010
Type	Article in Proceedings
Conference	XXXIV. Brněnské onkologické dny sborník
MU Faculty or unit	Faculty of Medicine
Citation
Field	Pneumology
Keywords	Erlotinib; NSCLC; serious adverse events; lowered dose
Description	The authors discuss Erlotinib treatment in patient with non-small cell lung cancer (NSCLC)and the effect of lowered dose in case of serious adverse events.
Related projects:	Environment - carcinogenesis - oncology